Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Clinical trial NCT05286801 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05286801
Sponsor: National Cancer Institute (NCI)
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Atypical Teratoid/Rhabdoid Tumor Epithelioid Sarcoma Kidney Medullary Carcinoma Malignant Solid Neoplasm Poorly Differentiated Chordoma Recurrent Atypical Teratoid/Rhabdoid Tumor Recurrent Chordoma Recurrent Epithelioid Sarcoma Recurrent Kidney Medullary Carcinoma Recurrent Malignant Solid Neoplasm Recurrent Rhabdoid Tumor Refractory Atypical Teratoid/Rhabdoid Tumor

Start date: 2022-11-17
Primary completion: 2030-03-31
Enrollment: 86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.